Barinthus Biotherapeutics (BRNS) Interest Expenses (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Interest Expenses came in at $13.9 million in Q1 2026, down 10.48% YoY from $15.5 million in Q1 2025, and up 106823.08% on a QoQ basis from $13000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Interest Expenses (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Interest Expenses data on file, last reported at $13.9 million in Q1 2026.
- Quarterly Interest Expenses fell 10.48% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (down 10.48% YoY) and the FY2025 annual result came in at $46.3 million, up 50.18% from the prior year.
- Interest Expenses improved to $13.9 million in Q1 2026, from $13000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $17.5 million in Q3 2023 to a low of -$1.5 million in Q4 2022.
- A 5-year average of $8.1 million and a median of $3.2 million in 2025 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 807.52% — and 2025, when it plunged 80.67%.
- Tracing BRNS's Interest Expenses over 5 years: stood at -$1.5 million in 2022, then soared by 100.45% to $7000.0 in 2023, then soared by 71.43% to $12000.0 in 2024, then climbed by 8.33% to $13000.0 in 2025, then soared by 106823.08% to $13.9 million in 2026.
- The last three Interest Expenses figures came in at $13.9 million (Q1 2026), $13000.0 (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | 14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.93 Mn |
| Jun 30, 2026 | 12.93 Mn |
| Mar 31, 2026 | 13.90 Mn |
| Mar 31, 2026 | 13.90 Mn |
| Dec 31, 2025 | 13,000.00 |
| Dec 31, 2025 | 13,000.00 |
| Sep 30, 2025 | 3.24 Mn |
| Sep 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 15.47 Mn |
| Jun 30, 2025 | 15.47 Mn |
| Mar 31, 2025 | 15.53 Mn |
| Mar 31, 2025 | 15.53 Mn |
| Dec 31, 2024 | 12,000.00 |
| Dec 31, 2024 | 12,000.00 |
| Sep 30, 2024 | 16.77 Mn |
| Sep 30, 2024 | 16.77 Mn |
| Jun 30, 2024 | 16.80 Mn |
| Jun 30, 2024 | 16.80 Mn |
| Mar 31, 2024 | 17.26 Mn |
| Mar 31, 2024 | 17.26 Mn |